4//SEC Filing
Sakiris Spiro Kevin 4
Accession 0001493152-23-036581
CIK 0001725430other
Filed
Oct 5, 8:00 PM ET
Accepted
Oct 6, 6:43 PM ET
Size
11.9 KB
Accession
0001493152-23-036581
Insider Transaction Report
Form 4
Sakiris Spiro Kevin
Chief Financial Officer
Transactions
- Purchase
Common Stock Warrants (Series E)
2023-10-04+112,727→ 112,727 total(indirect: Held by Anest Holdings Pty Ltd)Exp: 2029-04-04→ Common Stock (112,727 underlying) - Purchase
Common Stock
2023-10-04+112,727→ 117,427 total(indirect: Held by Anest Holdings Pty Ltd) - Purchase
Common Stock Warrants (Series F)
2023-10-04+112,727→ 112,727 total(indirect: Held by Anest Holdings Pty Ltd)Exp: 2025-04-04→ Common Stock (112,727 underlying)
Holdings
- 3,765
Common Stock
Footnotes (4)
- [F1]The reported securities are included within 112,727 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
- [F2]The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.
- [F3]The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).
- [F4]These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.
Documents
Issuer
INTELLIGENT BIO SOLUTIONS INC.
CIK 0001725430
Entity typeother
Related Parties
1- filerCIK 0001830957
Filing Metadata
- Form type
- 4
- Filed
- Oct 5, 8:00 PM ET
- Accepted
- Oct 6, 6:43 PM ET
- Size
- 11.9 KB